文献速递复苏、休克与脓毒症心脑血管急症

钙与安慰剂对院外心脏骤停患者远期结局的影响

Effect of calcium vs. placebo on long-term outcomes in patients with out-of-hospital cardiac arrest.
PubMed 文献 · Resuscitation · 2022-07-30
一句话结论COCA 试验远期随访显示,院外心脏骤停使用氯化钙组 1 年生存率与神经功能良好生存率均低于安慰剂组,结果不支持院外心脏骤停时使用钙剂。

COCA 试验为随机、安慰剂对照、双盲研究,纳入 ≥18 岁非创伤性院外心脏骤停且接受肾上腺素的患者,在首剂及第二剂肾上腺素后给予氯化钙 5 mmol 或生理盐水安慰剂,最多两剂。本文报告预设的 6 个月和 1 年生存、神经功能良好生存(改良 Rankin 量表 ≤3 分)及健康相关生活质量分析。共 391 例纳入分析:1 年时钙组 9 例(4.7%)存活 vs 安慰剂组 18 例(9.1%),风险比 0.51(95%CI 0.24–1.09);钙组 7 例(3.6%)神经功能良好生存 vs 安慰剂组 17 例(8.6%),风险比 0.42(95%CI 0.18–0.97)。健康相关生活质量结果同样提示钙剂可能有害,但置信区间宽、结果不精确。效应估计随时间保持稳定,提示钙剂可能有害但置信区间宽,结果不支持院外心脏骤停时使用钙剂。

要点

  • 1 年神经功能良好生存(mRS ≤3):钙组 7 例(3.6%)vs 安慰剂组 17 例(8.6%),风险比 0.42(95%CI 0.18–0.97)。
  • 1 年总生存:钙组 9 例(4.7%)vs 安慰剂组 18 例(9.1%),风险比 0.51(95%CI 0.24–1.09),未达统计学显著。
  • 钙剂用法为氯化钙 5 mmol,在首剂及第二剂肾上腺素后给药,最多两剂。
  • 健康相关生活质量结果同样提示钙剂可能有害,但置信区间宽、结果不精确。
  • 效应估计随时间保持稳定,结果不支持院外心脏骤停时使用钙剂。

适用人群与场景

  • 年龄 ≥18 岁、非创伤性院外心脏骤停且接受了肾上腺素的患者。

诊断标准与关键阈值

  • 神经功能良好结局定义为改良 Rankin 量表(mRS)≤3 分。

处置流程与药物剂量

  • 试验药物为氯化钙 5 mmol 或生理盐水安慰剂,在首剂肾上腺素后给予,并在第二剂肾上腺素后再次给予,最多两剂。

研究设计与关键结果

  • COCA 试验为随机、安慰剂对照、双盲试验,共分析 391 例患者。
  • 1 年生存:钙组 9 例(4.7%)vs 安慰剂组 18 例(9.1%),风险比 0.51(95%CI 0.24–1.09)。
  • 1 年神经功能良好生存(mRS ≤3):钙组 7 例(3.6%)vs 安慰剂组 17 例(8.6%),风险比 0.42(95%CI 0.18–0.97)。
  • 健康相关生活质量结果同样提示钙剂可能有害,但结果不精确、置信区间宽。

证据类型、等级与局限

  • 证据类型:随机、安慰剂对照、双盲试验的预设远期结局分析。
  • 局限:效应估计置信区间宽;健康相关生活质量结果不精确。

对床旁实践的改变

  • 作者认为,结果不支持院外心脏骤停时使用钙剂。

指南或共识出处

  • COCA 试验(Calcium for Out-of-hospital Cardiac Arrest),ClinicalTrials.gov 注册号 NCT04153435。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The Calcium for Out-of-hospital Cardiac Arrest (COCA) trial was a randomized, placebo-controlled, double-blind trial of calcium for out-of-hospital cardiac arrest. The primary and secondary outcomes have been reported previously. This article describes the long-term outcomes of the trial.

METHODS: Patients aged ≥18 years were included if they had a non-traumatic out-of-hospital cardiac arrest during which they received adrenaline. The trial drug consisted of calcium chloride (5 mmol) or saline placebo given after the first dose of adrenaline and again after the second dose of adrenaline for a maximum of two doses. This article presents pre-specified analyses of 6-month and 1-year outcomes for survival, survival with a favorable neurological outcome (modified Rankin Scale of 3 or less), and health-related quality of life.

RESULTS: A total of 391 patients were analyzed. At 1 year, 9 patients (4.7%) were alive in the calcium group while 18 (9.1%) were alive in the placebo group (risk ratio 0.51; 95% confidence interval 0.24, 1.09). At 1 year, 7 patients (3.6%) were alive with a favorable neurological outcome in the calcium group while 17 (8.6%) were alive with a favorable neurological outcome in the placebo group (risk ratio 0.42; 95% confidence interval 0.18, 0.97). Outcomes for health-related quality of life likewise suggested harm of calcium but results were imprecise with wide confidence intervals.

CONCLUSIONS: Effect estimates remained constant over time suggesting harm of calcium but with wide confidence intervals. The results do not support calcium administration during out-of-hospital cardiac arrest.

TRIAL REGISTRATION: ClinicalTrials.gov-number, NCT04153435.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Vallentin MF, Granfeldt A, Meilandt C, et al. Effect of calcium vs. placebo on long-term outcomes in patients with out-of-hospital cardiac arrest. Resuscitation. 2022. PMID: 35917866. doi:10.1016/j.resuscitation.2022.07.034

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。